Plenary speakers

Stefanie Dimmeler

Frankfurt, Germany

Monday 07 May PATHOGENESIS OF ATHEROSCLEROSIS

RNA editing controls atherosclerosis

Stefanie Dimmeler is Professor of Experimental Medicine and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt. She undertook her PhD at the University of Konstanz/Germany, and then completed a fellowship in Experimental Surgery at the University of Cologne, and in Molecular Cardiology at the University of Frankfurt. Dr. Dimmeler has received more than 17 awards for her research. She presented the George E. Brown Memorial Lecture and the Paul Dudley White International Lecture at the Scientific Sessions of the American Heart Association, as well as the Thomas W. Smith Memorial Lecture and the Michael Oliver Memorial Lecture at the British Atherosclerosis Society Autumn Meeting. Her research interests are understanding the basic mechanisms underlying cardiovascular disease and vessel growth, with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically non-coding RNAs.

David Erlinge

Lund, Sweden

Tuesday 08 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Strategies to treat vulnerable plaques

After completing his medical degree and PhD at Lund University, Sweden, David Erlinge undertook research studies in invasive cardiology at Cornell University, New York, NY. Dr. Erlinge was awarded the Lars Werkö distinguished research fellowship in 2006, and was appointed Professor in Cardiology at Lund University in 2008. His research is focused on acute coronary syndromes, platelet function and cardioprotection. Dr. Erlinge is a fellow of the American College of Cardiology and the European Society of Cardiology, and a member of the European Association of Percutaneous Cardiovascular Interventions and the American Heart Association, amongst others. He is also a former President of the Swedish Society of Cardiology. He has published extensively in high impact journals and written more than 240 original articles.

Brian A. Ference

Cambridge, United Kingdom

Tuesday 08 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Lessons from genetics: risk-score and novel candidates

Monday 30 November EBAC ACCREDITATION PENDING

Validating pharmacological targets by genetics: the case of ATP Citrate Lyase

Saturday 05 May The multifaceted aspects of cardiovascular prevention: from nutrition to therapy

Lifestyle and genetics an interaction contributing to cardiovascular risk

Monday 30 November BREAKING NEWS

LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS

Monday 30 November EBAC ACCREDITATION PENDING

Apo B containing lipoproteins a better target for CV risk reduction?

Brian Ference is Associate Professor of Medicine, Clinical Chief of the Division of Cardiovascular Medicine and Director of the Cardiovascular Genomic Research Centre at Wayne State University School of Medicine. He is currently on leave from those posts and living in Beijing where he is Chief Medical and Scientific Officer for the Chinese Precision Medicine Initiative US-Sino Collaboration, which is helping to design the next generation healthcare system based on a virtual cloud-based infrastructure and informed by personalized machine learning “prescriptive genomic” testing. Dr. Ference is also a member of the Leadership Council of the American College of Cardiology’s Section on the Prevention of Cardiovascular Disease. Dr. Ference is a cardiologist and genetic epidemiologist who was educated and trained at Harvard, Yale, Oxford and Cambridge Universities. His research focuses on the use of naturally randomized genetic evidence to 1) accelerate the drug discovery and development process by designing and conducting portfolios of “naturally randomized trials”; 2) identify patterns of polymorphism that define differential vulnerability to modifiable cardiovascular risk factors as a strategy to personalize the prevention of cardiovascular disease; and 3) frame and answer important public health questions to fill evidence gaps when an actual randomized trial would be either impossible or impractical to conduct thereby informing (and challenging) cardiovascular medicine treatment guidelines. He holds leadership positions in several international cardiovascular medicine professional societies.

Valentin Fuster

New York, USA

Sunday 06 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Imaging and CVD risk estimation (population studies)

Valentin Fuster is the Director of Mount Sinai Heart, The Richard Gorlin, MD Heart Foundation, Professor at the Icahn School of Medicine at Mount Sinai, and Physician-in-Chief, The Mount Sinai Hospital. Dr Fuster is a world-renowned cardiologist and an established global leader in the field of cardiovascular medicine, as recognized by the highest awards for research from the American Heart Association, American College of Cardiology and the European Society of Cardiology. Dr. Fuster has published more than 1,000 research studies and has been named Doctor Honoris Causa by thirty-six universities. He is a past President of the American Heart Association, past President of the World Heart Federation, member of the US National Academy of Medicine, where he chaired the Committee for the document on “Promotion of Cardiovascular Health Worldwide”, and was a former Council member of the US National Heart, Lung and Blood Institute and Chairman of the Training Program of the American College of Cardiology. He presently Co-Chairs the Advisory Committee on “The Role of the United States on Global Health” as advisor to the US President, and is a member of the European Horizon 2020 Scientific Panel of Health.

Ulf Landmesser

Berlin, Germany

Sunday 06 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Is there need to revise goals for lipid lowering?

Is it possible to prevent recurrent events?

Monday 30 November EBAC ACCREDITATION PENDING

A contemporary approach to dyslipidaemias, PCSK9 inhibition

PCSK9 inhibitors in CV risk: from data to clinical practice

Ulf Landmesser is Chairman of the Department of Cardiology at the Charité – Universitätsmedizin Berlin (CBF) since 2014. After completing his medical studies at the Medical School of Hannover, the University of Connecticut in Farmington (USA) and the National Heart & Lung Institute in London, he specialized in Internal Medicine and Cardiology at the Medical School of Hannover. In 2000/2001 he completed a post-doctoral fellowship in vascular biology at the Department of Cardiology, Emory University School of Medicine, Atlanta (USA) as a scholar of the Alexander von Humboldt Foundation. He was appointed Consultant Cardiologist at the Medical School of Hanover, Germany. In 2007 he became a Senior Consultant Cardiologist with a focus on acute and interventional cardiology, and translational cardiovascular research in the Department of Cardiology, University Hospital of Zurich, where he later acted as Vice-Chairman of the Department of Cardiology. Professor Landmesser received the Götz Award in 2012, the official award of the medical faculty of the University of Zurich. Since 2008 he has been Deputy Editor of The European Heart Journal.

Professor Landmesser has a particular research interest in lipids, vascular biology and coronary disease.

Peter Libby

Boston/Paris, USA/France

Sunday 06 May KEYNOTE LECTURE BY PROFESSOR PETER LIBBY

Anti-inflammatory therapy and resolution of inflammation, theory and practice

Monday 30 November BREAKING NEWS

NEW DATA ON THE CANTOS TRIAL

Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and the Mallinckrodt Professor of Medicine at Harvard Medical School (HMS). After completing his medical degree at the University of California, San Diego School of Medicine, Dr. Libby undertook a residency in internal medicine and a fellowship in cardiovascular disease at Peter Bent Brigham Hospital (now BWH), and a research fellowship in cellular physiology at HMS. He received an honorary doctorate from the University of Lille, France. Dr. Libby is board certified in internal medicine and cardiovascular disease.

Dr. Libby’s clinical and research interests include vascular biology, atherosclerosis and preventive cardiology. His research laboratory studies the messengers created by the body that may produce arterial plaque, as well as normal and abnormal function of smooth muscle and endothelial cells. Dr. Libby discovered that vascular wall cells can produce as well as respond to pro-inflammatory cytokines. This discovery suggested autocrine and paracrine cytokine inflammatory signaling in arterial disease, and laid the groundwork for a new field in atherosclerosis research in laboratories worldwide. Dr. Libby has fostered the rapid translation to the clinic of the concepts of inflammation in arterial pathophysiology that emerged from his own laboratory work over the last twenty years. He has inspired, enabled, and participated in a number of the clinical studies that have placed inflammation at the forefront of current thinking about the diagnosis, risk stratification, and therapeutic approaches to atherosclerotic cardiovascular disease.

Dr. Libby has received numerous awards for his research accomplishments, including the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), the Special Award of the Heart Failure Association of the European Society of Cardiology (2014), the Ernst Jung Gold Medal for Medicine (2016), and the Earl Benditt Award from the North American Vascular Biology Organization (2017). He has received a number of lifetime achievement awards from various organizations. Dr. Libby is a Consulting Editor to Circulation Research (since 2015), and an editorial board member of Arteriosclerosis Thrombosis, and Vascular Biology.

Dr. Libby has published extensively in numerous high impact journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald’s Heart Disease, having served as the Editor-in Chief of the 8th Edition, and has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. Dr. Libby has held numerous visiting professorships and delivered more than 100 major named or keynote lectures throughout the world.

 

 

Steffen Massberg

Munich, Germany

Tuesday 08 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Atherothrombosis; from pathogenesis to treatment

Steffen Massberg is Professor of Cardiology and Director of the Department of Cardiology at the University Clinic Munich, Ludwig-Maximilians University in Germany. His basic science research interests encompass stem-cell biology, platelet biology, mechanisms of arterial and venous thrombosis, immune-cell migration, immune-cell/coagulation crosstalk and bio-imaging (including 2-photon microscopy). Professor Massberg is the co-ordinator and lead scientist of the European FP7 project PRESTIGE (PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort). His awards include the Martin Villar Haemostasis Award (2011) and the Basic Science Award from the German Society of Cardiology (2012). Professor Massberg has published extensively in high-impact international journals, including Blood, Nature Reviews Immunology, The Journal of Experimental Medicine and Circulation.

Gerard Pasterkamp

Utrecht, The Netherlands

Monday 07 May PATHOGENESIS OF ATHEROSCLEROSIS

Shifting concepts in the description of the "vulnerable plaque"

Gerard Pasterkamp is Professor of the Laboratory of Clinical Chemistry at the University Medical Center Utrecht. His research interests focus on cardiovascular biology and innovation in biomarkers and drug targets to diagnose and treat atherosclerotic disease. The research group houses the largest atherosclerotic plaque biobank worldwide, Athero Express including more than 4500 patients. This biobank has generated new insights into determinants of plaque destabilization. The laboratory also invests in the excavation of genetic determinants of atherosclerotic plaque characteristics. Professor Pasterkamp has coordinated national and European Union based consortia aimed at unravelling biomarkers and mechanisms of atherosclerotic disease.

 

Ira Tabas

New York, USA

Monday 07 May PATHOGENESIS OF ATHEROSCLEROSIS

Defective inflammatory resolution in atherosclerosis: Mechanisms and therapeutic opportunities

Ira Tabas is the Richard J. Stock Professor of Medicine at Columbia University. He completed his MD/PhD at Washington University and his clinical training at Columbia. His laboratory studies the cellular biology of advanced atherosclerotic plaque progression and the cellular-molecular mechanisms linking insulin resistance to enhanced atherosclerosis.  His research has elucidated signalling pathways in macrophages that contribute to atherosclerosis, and in hepatocytes that contribute to pro-atherogenic insulin resistance. He has published in Cell, Nature, Science, Nature Cell Biology, Cell Metabolism and other leading peer-reviewed journals, and is also on Science’s Board of Reviewing Editors. His awards include election to the American Society for Clinical Investigation Association of American Physicians, American Heart Association (AHA) Established Investigator Award, Columbia University Lamport Research Award, AHA/Atherosclerosis Thrombosis Vascular Biology Council Special Recognition Award, Washington University Alumni Achievement Award, the Society of Leukocyte Biology Bonazinga award, the Harrington Discovery Institute Innovator-Scholar Award, and the AHA Ross Lectureship Award.

Dr. Tabas, Richard J. Stock Professor of Medicine, Columbia University, completed his M.D./Ph.D. at Washington University and his clinical training at Columbia. His research has elucidated signaling pathways in macrophages that contribute to atherosclerosis and in hepatocytes that contribute to pro-atherogenic insulin resistance. His papers have appeared in Cell, Nature, Science, Nature Cell Biology, Cell Metabolism and other top journals, and he is on Science’s Board of Reviewing Editors. His awards include election to ASCI/AAP, AHA Established Investigator Award, Columbia University Lamport Research Award, AHA/ATVB Council Special Recognition Award, Washington University Alumni Achievement Award, the Society of Leukocyte Biology Bonazinga award, the Harrington Discovery Institute Innovator-Scholar Award, and the AHA Ross Lectureship Award.

Marja-Riitta Taskinen

Helsinki, Finland

Monday 07 May KEYNOTE LECTURE BY PROFESSOR MARJA-RIITTA TASKINEN

Disturbances in hepatic and lipoprotein metabolism is the hallmark of atherogenic dyslipidaemia

Marja-Riitta Taskinen is Emerita Professor of Medicine and her team is a member of the Research Program Unit, Diabetes & Obesity Research program at the University of Helsinki. Her research team at Biomedicum Helsinki focuses on lipoprotein kinetics in health and metabolic disorders including diabetes and dyslipidaemias, as well as the genetics of familial dyslipidemias.

Professor Taskinen’s outstanding achievements have been recognized by several international associations. These include the Claude Bernard Award (European Association for Study of Diabetes [EASD] 2002), Edwin Bierman Award (American Diabetes Association 2004), Novartis Award (2006), the Pohjola and Suomi Mutual Medical Award by the Finnish Medical Foundation (2012), and the Jean Vague/Per Björntorp Award by the International Chair on Cardiometabolic Risk (May, 2017). In November 2017 , Professor Taskinen was awarded the prestigious Robert Levy Memorial lecture at the 2017 American Heart Association Scientific Sessions, Anaheim, California, USA.

Professor Taskinen has been extensively involved in the activities of the European Atherosclerosis Society (President of EAS 2006-2008), International Atherosclerosis Society, EASD and International Diabetes Federation. Professor Taskinen is a member of the European Society of Cardiology/EAS Guidelines Committee on Management of Dyslipidaemias and is also a member of EAS Consensus Panel. She has published extensively in high-impact journals (H-index 85).

Viola Vaccarino

Atlanta, USA

Sunday 06 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Stress, behavior and cardiovascular disease

Viola Vaccarino, M.D., Ph.D., is the Wilton Looney Chair of Cardiovascular Research, Professor of Epidemiology and Medicine, and Chair of the Department of Epidemiology at Emory University in Atlanta, USA. She received an M.D. from the University of Milan, Italy, and a Ph.D. in Epidemiology from Yale University. She is a recognized leader on mind-body relationships in heart disease and on the role of psychological stress, mental health and behavioral factors on cardiovascular risk. Dr.Vaccarino is particularly interested in the complex interplay of emotional and behavioural factors, such as depression, psychological stress, and socioeconomic status, with the autonomic system and genetic predisposition in the pathophysiology of cardiovascular disease.

Dr. Vaccarino is the author of over 300 peer-reviewed research publications and has an extensive record of research funding from the National Institutes of Health.

Renu Virmani

Gaithersburg, USA

Monday 07 May PATHOGENESIS OF ATHEROSCLEROSIS

Neoatherosclerosis from a pathologist's point of view

Renu Virmani is an internationally renowned cardiovascular pathologist and a leading researcher in the field of cardiovascular disease treatment.  Currently Dr. Virmani serves as the President of CVPath Institute, which she founded in 2005. Dr. Virmani is also Clinical Professor, Department of Pathology at Georgetown University; University of Maryland-Baltimore; George Washington University; and Vanderbilt University. She was a Chairperson at the Department of Cardiovascular Pathology of the Armed Forces Institute of Pathology from 1984 until 2004.  Dr. Virmani received her M.D. from Lady Hardinge Medical College, Delhi University, in New Delhi, India.

Dr. Virmani is the recipient of the TCT Career Achievement Award by the Cardiovascular Research Foundation (2012), and has also been recognized by the Council on Clinical Cardiology of the American Heart Association. She was awarded an honorary degree from the University of Antwerp, Belgium in 2008 and has also received honorary awards from the European Society of Cardiology (2008) and EuroPCR (2006). In 2010 she presented the Laennec Clinician Educator Lecture. Dr. Virmani is a Fellow of the American College of Cardiology, and is a member of the American Heart Association, and the U.S. and Canadian Academy of Pathology.

 Dr. Virmani lectures at scientific meetings, both nationally and internationally, and has delivered more than 800 presentations globally. She is responsible for multiple research grants in the field of cardiovascular pathology and has authored or co-authored over 700 publications in peer-reviewed journals in the field of atherosclerosis, vulnerable plaque, stents, and other cardiovascular diseases. She has edited 7 books and written over 100 book chapters. Dr. Virmani is also a manuscript reviewer for many scientific journals.

Joseph L. Witztum

La Jolla, USA

Tuesday 08 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Novel therapeutic approaches using antisense inhibition

Joseph L. Witztum is currently Distinguished Professor of Medicine at the University of California, San Diego. His basic research has provided an improved understanding of the role of oxidized low-density lipoprotein (LDL) and immunological mechanisms in atherogenesis and clinical atherosclerotic cardiovascular disease. Professor Witztum has also promoted the development of novel therapies for unmet clinical needs, especially in the context of hypertriglyceridaemia and elevated lipoprotein(a) levels. He has published more than 430 manuscripts and has been an Editor of major scientific journals in the field for the past 30 years.

 

Salim Yusuf

Hamilton, Canada

Sunday 06 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Lessons from epidemiology and environmental CVD risk factors

Saturday 05 May The multifaceted aspects of cardiovascular prevention: from nutrition to therapy

Diet and CVD - the epidemiological view

Salim Yusuf is an internationally renowned cardiologist and epidemiologist whose work over 35 years has substantially influenced prevention and treatment of cardiovascular disease. After completing his medical degree in Bangalore in 1976, Dr. Yusuf completed a Doctor of Philosophy at Oxford under a Rhodes Scholarship. During this time, he initiated the concepts of large, simple trials, and meta-analysis. He coordinated the International Studies of Infarct Survival trial which set the structure for future international collaborative work in cardiovascular disease and demonstrated the value of beta-blockers in myocardial infarction. In 1984, Dr. Yusuf moved to the National Institutes of Health in Bethesda, USA, where he was a leader in their Studies of Left Ventricular Dysfunction (SOLVD) trial (establishing the value of ACE inhibitors in left ventricular dysfunction) and DIG trial (clarifying the role of digitalis). In 1992 he moved to McMaster University, where he established an international programme of research in cardiovascular disease and prevention, culminating in the creation of the Population Health Research Institute, which he founded and heads.

Work by his group has led to a better understanding of risk factors for heart disease and strokes globally, and the discovery of new treatments such as ACE inhibitors, dual antiplatelet, and novel antithrombotic agents to reduce cardiovascular events and mortality. His current work explores the role of the environment, health policies and health systems in influencing cardiovascular disease mortality globally. Dr. Yusuf holds a Heart and Stroke Foundation of Ontario Research Chair, has received more than 40 international and national awards for research and in 2014 was inducted into the Royal Society of Canada and appointed as an Officer of the Order of Canada.